Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human phase 1/2 study of SAR445877 alone or in combinations for advanced solid tumors
jRCT2031250535Phase 2Active, not recruiting
- Sponsor
- Sanofi
- Start
- Jan 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
01
Overview
Phase 2, open-label trial of SAR445877 in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC) and 7 more (17 arms), sponsored by Sanofi. Primary endpoints: Dose-limiting toxicities in Part 1A and Japan Cohort F, Dose-limiting toxicities in Part 1B and 2 more. Started Jan 2026; status: active, not recruiting.
02
Drugs
SAR445877
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)hepatocellular carcinoma (HCC)gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on jRCT2031250535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250535.